Analyst firms · Barclays · ILMN

Barclays ILMN price target and rating history

Illumina Inc. (ILMN) · Health Care

Barclays rates Illumina Inc. (ILMN) Underweight with a $100 price target, as of its latest action on Feb 10, 2025. It has published 8 rating actions on ILMN since July 2021, including 3 upgrades and 2 downgrades. Across 5 firms with a ILMN price target in the last 12 months, the median target is $185.

Current rating
Underweight
Price target
$100
Median target, all firms
$185
Actions on ILMN
8

Barclays price target on ILMN

$400$250$10020222023202420252026
Barclays price target on ILMN, each point a stated target, July 2021 to February 2025.

Every Barclays rating on ILMN

How other firms rate ILMN

Each firm's latest rating and stated target in the last 12 months.

FirmRatingPrice targetDate
StephensEqual-Weight$275Oct 23, 2026
UBSBuy$260Sep 9, 2026
BernsteinMkt Perform$185Jun 26, 2026
RBC Capital MarketsOutperform$170May 15, 2026
DaiwaOutperform$155May 14, 2026

Questions about Barclays and ILMN

What is Barclays's price target for ILMN?
Barclays's latest stated price target for Illumina Inc. (ILMN) is $100, from its action on Feb 10, 2025.
What is Barclays's rating on ILMN?
Barclays rates ILMN Underweight, a bearish rating, as of Feb 10, 2025.
When did Barclays last change its view on ILMN?
On Feb 10, 2025, Barclays downgrades to Underweight from Equal Weight, price target $130 to $100.
How does Barclays's ILMN target compare with other analysts?
Across 5 firms with a ILMN price target in the last 12 months, the median target is $185.

More ILMN rating histories

All Barclays ratingsILMN news and filingsEvery analyst firm

From rating actions in the Quantisnow feed. A target holds until the firm states a new one; a reiteration with no target keeps the last one. Not investment advice.